C
Carl Harries
Researcher at Imperial College London
Publications - 31
Citations - 1169
Carl Harries is an academic researcher from Imperial College London. The author has contributed to research in topics: Pulmonary hypertension & Eisenmenger syndrome. The author has an hindex of 12, co-authored 29 publications receiving 1007 citations. Previous affiliations of Carl Harries include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study.
Gerhard-Paul Diller,Konstantinos Dimopoulos,Craig S. Broberg,Mehmet Gungor Kaya,Utpal Singh Naghotra,Anselm Uebing,Carl Harries,Omer Goktekin,J. Simon R. Gibbs,J. Simon R. Gibbs,Michael A. Gatzoulis +10 more
TL;DR: Markers of heart failure and parameters associated with arrhythmia are of prognostic value in terms of mortality and may guide clinicians caring for Eisenmenger patients.
Journal ArticleDOI
Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease.
Craig S. Broberg,Bridget E. Bax,Darlington O. Okonko,M.W. Rampling,Stephanie Bayne,Carl Harries,Simon J. Davidson,Anselm Uebing,Arif Anis Khan,Swee Lay Thein,J. Simon R. Gibbs,J. Simon R. Gibbs,John F. Burman,Michael A. Gatzoulis +13 more
TL;DR: Iron deficiency is common in cyanotic adults but does not alter viscosity, and hyperviscosity symptoms are associated with a higher Hct-adjusted viscosities independent of cell size or iron stores.
Journal ArticleDOI
emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension.
Janelle Yorke,Paul A. Corris,Sean Gaine,J. Simon R. Gibbs,J. Simon R. Gibbs,David G. Kiely,Carl Harries,Val Pollock,Iain Armstrong,Iain Armstrong +9 more
TL;DR: The emPHasis-10 questionnaire as discussed by the authors is a short questionnaire for assessing health-related quality of life in pulmonary arterial hypertension patients, which has excellent measurement properties and is sensitive to differences in relevant clinical parameters.
Journal ArticleDOI
Safety and tolerability of bosentan in adults with Eisenmenger physiology
Michael A. Gatzoulis,Paula Rogers,Wei Li,Carl Harries,Derek Cramer,Simon Ward,Ghada W. Mikhail,J. Simon R. Gibbs +7 more
TL;DR: Bosentan was safe and well tolerated in adults with Eisenmenger physiology both at initiation and after 3 months of oral therapy, and clinical status of patients and pulmonary haemodynamics appeared to improve.
Journal ArticleDOI
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease
Gerhard-Paul Diller,Konstantinos Dimopoulos,Mehmet Gungor Kaya,Carl Harries,Anselm Uebing,Wei Li,Evdokia Koltsida,J. Simon R. Gibbs,Michael A. Gatzoulis +8 more
TL;DR: Bosentan appears to be safe and well tolerated in adults with pulmonary arterial hypertension associated with congenital heart disease or Eisenmenger’s syndrome during mid- to long-term follow-up and functional class and the 6-minute walk test distance improved and this effect was maintained for up to 2 years of bosentan treatment.